The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbitsPAXTON, J. W.Journal of pharmacy and pharmacology. 1986, Vol 38, Num 11, pp 837-840, issn 0022-3573Article

Absence of effect of propoxyphene on antipyrine kinetics in the rabbitPAXTON, J. W.Pharmacology. 1983, Vol 27, Num 4, pp 241-244, issn 0031-7012Article

Interaction of probenecid with the protein binding of methotrexatePAXTON, J. W.Pharmacology. 1984, Vol 28, Num 2, pp 86-89, issn 0031-7012Article

Determination of N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino]-4-acridinecarboxamide in plasma by high-performance liquid chromatographyJURLINA, J. L; PAXTON, J. W.Journal of chromatography. 1985, Vol 342, Num 2, pp 431-435, issn 0021-9673Article

Elimination kinetics of amsacrine in the rabbit: evidence of nonlinearityPAXTON, J. W; JURLINA, J. L.Pharmacology. 1985, Vol 31, Num 1, pp 50-56, issn 0031-7012Article

Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugsCORNFORD, E. M; YOUNG, D; PAXTON, J. W et al.Cancer chemotherapy and pharmacology. 1992, Vol 29, Num 6, pp 439-444, issn 0344-5704Article

Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino]-4-acridinecarboxamide in rabbitsPAXTON, J. W; JURLINA, J. L.Cancer chemotherapy and pharmacology. 1986, Vol 16, Num 3, pp 253-256, issn 0344-5704Article

Propranolol disposition after acute myocardial infarctionPAXTON, J. W; NORRIS, R. M.Clinical pharmacology and therapeutics. 1984, Vol 36, Num 3, pp 337-342, issn 0009-9236Article

High-performance liquid chromatographic method for the determination of 4'-(9-acridinylamino)methanesulfon-m-anisidide in plasmaJURLINA, J. L; PAXTON, J. W.Journal of chromatography. 1983, Vol 276, Num 2, pp 367-374, issn 0021-9673Article

Propranolol binding in serum: comparison of methods and investigation of effects of drug concentration, pH, and temperaturePAXTON, J. W; CALDER, R. L.Journal of pharmacological methods. 1983, Vol 10, Num 1, pp 1-11, issn 0160-5402Article

Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivoZHOU, S. F; TINGLE, M. D; KESTELL, P et al.Xenobiotica (London. Print). 2002, Vol 32, Num 2, pp 87-107, issn 0049-8254Article

Effects of phenytoin on cognitive-motor performance in children as a function of drug concentration, seizure type, and time of medicationAMAN, M. G; WERRY, J. S; PAXTON, J. W et al.Epilepsia (Copenhagen). 1994, Vol 35, Num 1, pp 172-180, issn 0013-9580Article

Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humansPAXTON, J. W; YOUNG, D; ROBERTSON, I. G. C et al.Cancer chemotherapy and pharmacology. 1993, Vol 32, Num 4, pp 323-325, issn 0344-5704Article

Sustained release of a corticosteroid using polymeric implantsCAWLEY, S; ORMROD, D. J; PAXTON, J. W et al.Collection sécurité. 1986, Vol 19, Num 3-4, pp 233-243, issn 0538-4818Article

The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbitPAXTON, J. W; FOOTE, S. E; SINGH, R. M et al.Cancer chemotherapy and pharmacology. 1986, Vol 18, Num 3, pp 208-212, issn 0344-5704Article

Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemiaJURLINA, J. L; VARCOE, A. R; PAXTON, J. W et al.Cancer chemotherapy and pharmacology. 1985, Vol 14, Num 1, pp 21-25, issn 0344-5704Article

Identification and reactivity of the major metabolite (β-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humansZHOU, S. F; PAXTON, J. W; TINGLE, M. D et al.Xenobiotica (London. Print). 2001, Vol 31, Num 5, pp 277-293, issn 0049-8254Article

Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvationGALETTIS, P; CARR, J. L; PAXTON, J. W et al.Journal of analytical atomic spectrometry (Print). 1999, Vol 14, Num 6, pp 953-956, issn 0267-9477Article

Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brainCORNFORD, E. M; YOUND, D; PAXTON, J. W et al.Cancer research (Baltimore). 1992, Vol 52, Num 1, pp 138-143, issn 0008-5472Article

Disposition of amsacrine and its analogue 9-({2-methoxy-4-[(methylsulfonyl)-amino]phenyl}amino)-N,5-dimethyl-4-acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in miceKESTELL, P; PAXTON, J. W; EVANS, P. C et al.Cancer research (Baltimore). 1990, Vol 50, Num 3, pp 503-508, issn 0008-5472Article

Effects of carbamazepine on psychomotor performance in children as a function of drug concentration, seizure type, and time of medicationAMAN, M. G; WERRY, J. S; PAXTON, J. W et al.Epilepsia (Copenhagen). 1990, Vol 31, Num 1, pp 51-60, issn 0013-9580Article

Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humansPAXTON, J. W; KIM, S. N; WHITFIELD, L. R et al.Cancer research (Baltimore). 1990, Vol 50, Num 9, pp 2692-2697, issn 0008-5472, 6 p.Article

Expression, localisation and activity of ATP binding cassette (ABC) family of drug transporters in human amnion membranesAYE, I. L. M. H; PAXTON, J. W; EVSEENKO, D. A et al.Placenta (Eastbourne). 2007, Vol 28, Num 8-9, pp 868-877, issn 0143-4004, 10 p.Article

Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trialSCHOFIELD, P. C; ROBERTSON, I. G. C; PAXTON, J. W et al.Cancer chemotherapy and pharmacology. 1999, Vol 44, Num 1, pp 51-58, issn 0344-5704Article

Page / 3